Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 169 participants.

Also called NCT03635996

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 169 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03635996
Other papers using this trial's data
  • Etripamil Nasal Spray for Conversion of Repeated Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia During Long-Term Follow-Up: Results From the NODE-302 Study Journal of the American Heart Association, 2023-10-03 DOI, PubMed 37753718, PMC10727262 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT03635996. Allocation not applicable; no masking; primary purpose treatment. Start 2018-12-10 (actual); primary completion 2020-11-13 (actual). Results posted on 2023-04-24.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302
Condition
Paroxysmal Supraventricular Tachycardia
Intervention (Drug)
Etripamil NS 70 mg
Intervention (Device)
Aptar Pharma Nasal Spray Bidose System
Lead sponsor
Milestone Pharmaceuticals Inc. (class: other)
Collaborator
Medpace, Inc. (class: industry)

Record details

Record id
cardio:ct-nct03635996
Content hash
c92652334f1d0400a6ba4157e9b0814ca6b17fb5fd81deb6cc4ca29b16ecd05e